Avanza Fonder AB Buys New Position in Twist Bioscience Co. (NASDAQ:TWST)

Avanza Fonder AB acquired a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,791 shares of the company's stock, valued at approximately $1,059,000.

Other large investors have also recently made changes to their positions in the company. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after buying an additional 306 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock valued at $457,000 after purchasing an additional 312 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Twist Bioscience by 2.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock valued at $734,000 after purchasing an additional 363 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares in the last quarter. Finally, D.A. Davidson & CO. lifted its position in shares of Twist Bioscience by 3.5% during the 3rd quarter. D.A. Davidson & CO. now owns 19,618 shares of the company's stock worth $886,000 after buying an additional 664 shares in the last quarter.

Twist Bioscience Stock Performance

Twist Bioscience stock traded up $1.69 during mid-day trading on Monday, hitting $47.56. 616,749 shares of the company traded hands, compared to its average volume of 658,357. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -13.21 and a beta of 1.85. The stock has a fifty day moving average price of $46.47 and a 200-day moving average price of $46.30.

Analysts Set New Price Targets

A number of brokerages recently commented on TWST. Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Robert W. Baird increased their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday, November 19th. Barclays dropped their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Leerink Partners lifted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Finally, Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.90.

Insider Activity

In other Twist Bioscience news, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the transaction, the chief accounting officer now directly owns 45,620 shares of the company's stock, valued at $2,034,652. The trade was a 3.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Patrick John Finn sold 2,261 shares of the stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $43.09, for a total value of $97,426.49. Following the sale, the chief operating officer now directly owns 159,483 shares of the company's stock, valued at approximately $6,872,122.47. This trade represents a 1.40 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,640 shares of company stock worth $4,123,772. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.